Private Advisor Group LLC Sells 13,156 Shares of Teva Pharmaceutical Industries Ltd (TEVA)

Private Advisor Group LLC reduced its position in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 61.2% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 8,357 shares of the company’s stock after selling 13,156 shares during the quarter. Private Advisor Group LLC’s holdings in Teva Pharmaceutical Industries were worth $204,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in TEVA. Caisse DE Depot ET Placement DU Quebec raised its holdings in Teva Pharmaceutical Industries by 232.0% during the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 1,089,608 shares of the company’s stock worth $18,621,000 after purchasing an additional 761,380 shares during the last quarter. OppenheimerFunds Inc. increased its stake in shares of Teva Pharmaceutical Industries by 15.5% in the 1st quarter. OppenheimerFunds Inc. now owns 4,229,508 shares of the company’s stock valued at $72,282,000 after acquiring an additional 566,300 shares during the last quarter. Strs Ohio increased its stake in shares of Teva Pharmaceutical Industries by 76.7% in the 2nd quarter. Strs Ohio now owns 857,143 shares of the company’s stock valued at $20,845,000 after acquiring an additional 372,150 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 1st quarter valued at about $6,092,000. Finally, Acadian Asset Management LLC increased its stake in shares of Teva Pharmaceutical Industries by 2,710.0% in the 2nd quarter. Acadian Asset Management LLC now owns 312,702 shares of the company’s stock valued at $7,602,000 after acquiring an additional 301,574 shares during the last quarter. 64.52% of the stock is owned by hedge funds and other institutional investors.

In related news, EVP Iris Beck Codner sold 4,165 shares of the stock in a transaction that occurred on Thursday, August 9th. The stock was sold at an average price of $22.70, for a total transaction of $94,545.50. Following the completion of the sale, the executive vice president now directly owns 8,290 shares of the company’s stock, valued at approximately $188,183. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Sven Dethlefs bought 2,000 shares of the stock in a transaction that occurred on Friday, August 3rd. The shares were acquired at an average cost of $21.92 per share, with a total value of $43,840.00. Following the completion of the purchase, the executive vice president now owns 6,445 shares in the company, valued at approximately $141,274.40. The disclosure for this purchase can be found here. 0.43% of the stock is currently owned by corporate insiders.

NYSE TEVA opened at $22.85 on Friday. Teva Pharmaceutical Industries Ltd has a 52-week low of $10.85 and a 52-week high of $25.96. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.03 and a quick ratio of 0.69. The company has a market cap of $22.57 billion, a P/E ratio of 5.81, a price-to-earnings-growth ratio of 2.77 and a beta of 0.69.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Thursday, August 2nd. The company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.14. Teva Pharmaceutical Industries had a positive return on equity of 19.92% and a negative net margin of 47.98%. The business had revenue of $4.70 billion during the quarter, compared to analysts’ expectations of $4.75 billion. During the same period in the prior year, the business earned $1.02 EPS. Teva Pharmaceutical Industries’s revenue for the quarter was down 17.8% compared to the same quarter last year. sell-side analysts expect that Teva Pharmaceutical Industries Ltd will post 2.67 earnings per share for the current year.

A number of analysts have recently commented on the company. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $25.00 price target on shares of Teva Pharmaceutical Industries in a research note on Friday. Royal Bank of Canada reaffirmed a “hold” rating and issued a $19.00 price target on shares of Teva Pharmaceutical Industries in a research note on Tuesday, July 31st. Oppenheimer reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Thursday, August 2nd. Morgan Stanley upped their price target on Teva Pharmaceutical Industries from $19.00 to $20.00 and gave the company an “equal weight” rating in a research note on Friday, August 3rd. Finally, Citigroup set a $25.00 price target on Teva Pharmaceutical Industries and gave the company a “buy” rating in a research note on Thursday, May 31st. Eight equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $20.91.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Recommended Story: Risk Tolerance and Your Investment Decisions

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply